3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
3
Recruiting
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
21
Neoplasms
6
Neoplasm Metastasis
5
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hereditary Sensory and Autonomic Neuropathies
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Breast Diseases
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumor, Adult
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Rare Tumor
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm, Residual
1
Melanoma
1
Medulloblastoma
1
Malignant Female Reproductive System Neoplasm
1
Lung Neoplasms
1
Interventions
Bevacizumab
77
Fluorouracil
55
Cetuximab
48
Oxaliplatin
43
Leucovorin
42
pembrolizumab
37
Irinotecan
33
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
19
trifluridine tipiracil drug combination
17
Panitumumab
15
Blood Specimen Collection
15
Nivolumab
14
Magnetic Resonance Spectroscopy
14
regorafenib
13
Biopsy
13
Trifluridine
12
Gemcitabine
12
Cisplatin
12
Standard of Care
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
10
Cyclophosphamide
9
tislelizumab
8
Trastuzumab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
palbociclib
×
Clear all
NCT06307249
2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1
Recruiting
50 enrolled
NCT05725200
2023-02-21
EVIDENT
Oslo University Hospital
Phase 2
Recruiting
40 enrolled